Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Strong
Garp
Very Strong
Mqv Small
Neutral
Value
Consensus
Price
Very Strong
Earnings
Very Weak
Earnings
Strong
Dividends
Very Weak
Capital Efficiency
Very Strong
Balance Sheet
Very Weak
Website
NRX Pharmaceuticals, Inc.
Telephone
1.484.254.6134
Address
Suite 600, 1201 Orange Street, Wilmington, DE 19801
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.62 - 3.84
Trade Value (12mth)
US$415,249.00
1 week
-7.62%
1 month
2.71%
YTD
15.65%
1 year
15.21%
All time high
769.90
EPS 3 yr Growth
-77.90%
EBITDA Margin
NaN%
Operating Cashflow
-$14m
Free Cash Flow Return
0.00%
ROIC
0.00%
Interest Coverage
-23.90
Quick Ratio
0.30
Shares Outstanding (Fully Diluted)
32m
HALO Sector
Other Finance
Next Company Report Date
01-Apr-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 16 May 26 | |
| 16 May 26 | |
| 16 May 26 | |
| 25 March 26 | |
| 18 February 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -3.98 | -2.36 | -1.34 | | | | ||
EPS (Fully Diluted) | $ | | | | | -3.98 | -2.36 | -1.34 | | | | ||
Growth | % | | | | | 34.1 | 40.7 | 43.3 | | | | ||
PE | X | | | | | N/A | N/A | 458.2 | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
